title: Low Resistance Thought Induction Sleep-regulating Technique (TIP3-2) combined with medication for primary insomnia: a randomized controlled trial.
abstract: BACKGROUND
  Cognitive behavioral therapy for insomnia (CBT-I) is well-validated in the western countries. However, it has not been widely adopted or disseminated in China. One possibility is that therapeutic approaches drawn from traditional Chinese medicine (TCM) will be more widely accepted.
  
  
  OBJECTIVE
  This study aimed to evaluate the efficacy of medication in combination with a therapeutic approach drawn from TCM, Low Resistance Thought Induction Sleep-regulating Technique (TIP3-2), for acute treatment of insomnia.
  
  
  METHODS
  A randomized controlled trial was conducted. Ninety primary insomnia patients were randomly assigned to receive TIP3-2 combined with medication (n = 45) or medication only (n = 45) for 4 weeks. Medication consisted of 1-2 mg Estazolam nightly. On the basis of taking Estazolam, TIP3-2 combined with medication group was given Low Resistance Thought Induction Sleep-regulating Technique (TIP3-2) treatment twice a week. Outcomes were assessed with the Pittsburgh sleep quality index (PSQI) and polysomnography (PSG) before and after treatment.
  
  
  RESULTS
  Both groups demonstrated significant improvements in the PSQI and polysomnography indices. The TIP3-2+ medication group demonstrated a significant difference between the two groups in PSQI total score, sleep medication use, daytime dysfunction, subjective sleep quality, as well as polysomnography indices of sleep efficiency and awakening times (P < 0.05).
  
  
  CONCLUSIONS
  Among patients with primary insomnia, the addition of TIP3-2 provided benefits above and beyond the role of medication alone.
authors.affiliation: Psychology and Sleep Department of Guang'anmen Hospital of China Academy of Chinese Medical Sciences, No. 5 Bei Xian Ge, Xi Cheng District, Beijing, 100053, China, prof_wwd@sohu.com.
authors.forename: Wei-dong
authors.initials: WD
authors.lastname: Wang
authors.forename: Gui-xia
authors.initials: GX
authors.lastname: Li
authors.forename: Lan
authors.initials: L
authors.lastname: Hong
authors.forename: Yan-jiao
authors.initials: YJ
authors.lastname: Liu
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhao
authors.forename: Ying-na
authors.initials: YN
authors.lastname: Lin
authors.forename: Fang
authors.initials: F
authors.lastname: Wang
authors.forename: Tao
authors.initials: T
authors.lastname: Li
authors.forename: Xue
authors.initials: X
authors.lastname: Yan
authors.forename: Yan-ying
authors.initials: YY
authors.lastname: Huang
mesh_terms: D000328:Adult; D002681:China; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D003131:Combined Modality Therapy; D004949:Estazolam / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D007319:Sleep Initiation and Maintenance Disorders / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D006993:Hypnotics and Sedatives; D004949:Estazolam